Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models

Journal:

Science Translational Medicine

Published:

2025-08-06

DOI:

10.1126/scitranslmed.adn5400

Affiliations:

10

Authors:

22

Go to article

Institutions	Authors	Share
Princess Margaret Cancer Centre, U of T, Canada	9.000000	0.41
The University of Alabama at Birmingham (UAB), United States of America (USA)	4.000000	0.18
O'Neal Comprehensive Cancer Center at UAB, United States of America (USA)	3.000000	0.14
St. Jude Children's Research Hospital (St. Jude), United States of America (USA)	3.000000	0.14
University of Toronto (U of T), Canada	2.000000	0.09
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05

Interested in Oncology and Carcinogenesis?